Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Ties Up with Swiss Peer in Immuno-Oncology Drug Discovery
November 2, 2022
- Astellas’ Half-Year Revenue Up 17% on FX Boon; Xtandi US Sales Stall
November 2, 2022
- Daiichi Sankyo Nets Double-Digit Rise in H1 Sales as Major Products Fare Well
November 1, 2022
- Shionogi’s H1 Operating Profit Sinks 33.8% on COVID-Linked R&D Expenses
November 1, 2022
- Otsuka Logs 13.6% Growth in 9-Month Pharma Sales on 4 Global Products
November 1, 2022
- Sumitomo Braced for Red Ink to Continue in FY2023 on Latuda LOE
November 1, 2022
- Sumitomo Posts 7.3 Billion Yen Net Loss in H1 on Kynmobi Write-Down
November 1, 2022
- Ono’s April-September Sales Zoom 24.5% on Bullish Opdivo and Forxiga
November 1, 2022
- Takeda, Shionogi to Wind Up Copromotion for 2 ADHD Products
November 1, 2022
- Average Price Gap for 2023 Revision Looks to Be a Bit Lower than 7.6%: Wholesalers
November 1, 2022
- Novartis Challenges US Court Verdict on Tafinlar Patent Infringement
October 31, 2022
- Kyowa Kirin Files Hyperphosphatemia Drug in Japan
October 31, 2022
- Hisamitsu’s Osteoarthritis Patch Drug Fails in US PIII Study
October 31, 2022
- Opdivo Snags South Korea Nod for Neoadjuvant Use in NSCLC
October 31, 2022
- Takeda’s H1 Sales Up 10% Backed by Robust Mainstays, Hefty FX Gains
October 28, 2022
- Cancer-Savvy New CMO Eager to Extend Astellas’ Oncology Portfolio, Bag Speedy Approval
October 28, 2022
- Takeda Files SC Immunoglobulin for Immune Disorders in Japan
October 27, 2022
- Sanofi Seeks Dupixent’s Pediatric Dosage for Eczema in Japan
October 27, 2022
- Astellas Bags Option Rights to 2 Taysha Gene Therapy Programs
October 26, 2022
- Toho Picked as Single Wholesaler for LEO Pharma’s Dovonex
October 26, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…